Cohance Lifesciences Ltd (formerly known as SMS Lifesciences India Ltd) is a leading Indian contract research and manufacturing services (CRAMS) company specializing in complex active pharmaceutical ingredients (APIs), advanced intermediates, and drug delivery systems. Headquartered in Hyderabad, the company serves global innovator pharma companies across the US, Europe, and Japan. With a strong focus on R&D, regulatory compliance, and niche molecule synthesis, Cohance has built a reputation for high-quality, differentiated offerings. The company rebranded from SMS Lifesciences to Cohance Lifesciences in 2024 to reflect its strategic evolution. Despite recent profit contraction, it maintains a robust order book and long-term client relationships. This article provides a data-backed outlook on the Cohance Lifesciences share price target 2026–2030.
Cohance Lifesciences Ltd: Company Overview
- Former Name: SMS Lifesciences India Ltd (changed to Cohance Lifesciences in 2024)
- Headquarters: Hyderabad, Telangana
- Key Segments: CRAMS (Contract Research & Manufacturing Services), Complex APIs, Advanced Intermediates, Drug Delivery Systems
- Strategic Edge: Focus on high-barrier, regulated markets; strong IP-driven molecule portfolio
- Global Presence: Exports to 80+ countries; key clients include top 10 global pharma companies
Cohance benefits from India’s rising prominence in global pharma outsourcing and the shift toward complex, low-volume, high-value molecules. However, it faces margin pressure from R&D intensity and regulatory costs.
Cohance Lifesciences Ltd: Key Financial Snapshot
| Metric | Value |
|---|---|
| Current Share Price | ₹378.00 |
| Market Capitalization | ₹14,461.04 Cr |
| No. of Shares Outstanding | 38.26 Cr |
| 52-Week High / Low | ₹910 / ₹340 |
| P/E Ratio (TTM) | 52.10 |
| P/B Ratio | 3.28 |
| EPS (TTM) | ₹7.25 |
| Book Value (TTM) | ₹115.25 |
| ROE | 12.56% |
| ROCE | 16.14% |
| Dividend Yield | 0.00% |
| Face Value | ₹1 |
| Cash | ₹22.62 Cr |
| Total Debt | ₹70 Cr |
| Debt-to-Equity | 0.01 |
| Sales Growth (YoY) | 4.01% |
| Profit Growth (YoY) | -8.35% |
| Promoter Holding | 57.49% |
Cohance Lifesciences Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹400 – ₹450 |
| 2027 | ₹430 – ₹490 |
| 2028 | ₹460 – ₹540 |
| 2029 | ₹490 – ₹590 |
| 2030 | ₹520 – ₹640 |
Cohance Lifesciences Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹400 | ₹450 |
Cohance reported a 4% sales increase but an 8.35% profit decline in FY2025, driven by higher R&D expenses and one-time regulatory compliance costs. Trading at a P/E of 52.1x—rich for a company with falling profits—the stock appears overvalued unless earnings rebound sharply. A 2026 target of ₹400–₹450 assumes margin stabilization and no major client losses.
Cohance Lifesciences Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹430 | ₹490 |
The company’s pipeline of 120+ molecules and 30+ commercial products offers long-term visibility. If EPS recovers to ₹8.50–₹9.20 by FY27 and P/E moderates to 48–50x, the 2027 range of ₹430–₹490 is realistic—but remains speculative without profit growth resumption.
Cohance Lifesciences Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹460 | ₹540 |
By 2028, benefits from new commercial launches and higher-margin integrated services should reflect in profitability. Assuming EPS of ₹9.50–₹10.50 and P/E of 46–48x, the ₹460–₹540 band is justified—if execution stays on track.
Cohance Lifesciences Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹490 | ₹590 |
Long-term tailwinds include global pharma outsourcing and India’s CRAMS leadership. Risks include regulatory delays and client concentration. Using a P/E of 45–48x on projected EPS (~₹10–₹11.50), the 2029 target is ₹490–₹590.
Cohance Lifesciences Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹520 | ₹640 |
Over a five-year horizon, Cohance’s value hinges on the successful commercialization of its pipeline. A terminal P/E of 45–50x on FY30 EPS (~₹10.50–₹12.80) supports the ₹520–₹640 range.
Cohance Lifesciences Ltd: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Promoters | 57.49% |
| Domestic Institutional Investors (DII) | 21.59% |
| Public & Retail | 14.92% |
| Foreign Institutional Investors (FII) | 6.01% |
| Others | 0.00% |
High promoter holding ensures strategic continuity, while rising DII interest reflects confidence in governance.
Cohance Lifesciences Ltd: Strengths vs Risks
Strengths:
- Near-zero debt (D/E: 0.01) and a strong client base in regulated markets
- Focus on high-barrier, complex molecules with long lifecycle
- Rebranded to “Cohance” to align with global identity
- Strong R&D pipeline with 120+ molecules under development
Risks:
- Extremely high P/E (52.1x) with negative profit growth (-8.35%)—valuation mismatch
- Very low cash reserves (₹22.6 Cr) relative to market cap
- No dividend payout (0% yield) limits income appeal
- Stock fell ~58% from the 52-week high due to earnings concerns
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | High |
| Ideal Time Horizon | 5+ years |
| Volatility | Very high (small-cap pharma stock) |
| Dividend/Income Potential | None (0% yield) |
| Best For | Aggressive growth investors comfortable with pre-profit-recovery pharma stocks |
- Declining profits despite sales growth
- Concerns over R&D ROI and margin pressure
- Broader de-rating of small-cap pharma stocks
Final Verdict
Cohance Lifesciences is a high-potential but high-risk bet on India’s CRAMS leadership. While its molecule pipeline and client base are strong, the current valuation demands near-perfect execution. Our Cohance Lifesciences share price target 2026–2030 (₹400 to ₹640) reflects cautious optimism—contingent on profit recovery and margin improvement. Suitable only for aggressive, long-term portfolios.
Disclaimer: Price targets are estimates based on publicly available data and sector analysis. They are not investment advice. Consult a SEBI-registered advisor before making decisions.
Sources
- Screener.in – Cohance Lifesciences Consolidated Page (FY2025 + TTM)
- Finology Ticker – COHANCE Financial Ratios & Valuation
- Cohance Investor Presentation (Q3 FY26, Jan 2026)
- BSE India – Annual Report FY2025
- Ministry of Chemicals & Fertilizers – Pharma Export Policy Updates
